Artificial intelligence (AI) is slowly changing and reshaping industries, from banking to telecom.
However, there are certain things AI can’t do — and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, hard-to-treat or even impossible-to-treat conditions could deliver returns on par with some AI leaders.
Here is one serious candidate to consider along those lines. This biotech company is somewhat risky, but it could generate strong returns in the long run.
This post originally appeared at The Motley Fool.